New scanner aims to sharpen cancer scans
NCT ID NCT07242690
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This pilot study tests whether a newer type of CT scanner (photon counting detector CT, or PCD-CT) can improve the quality of PET images for people with head and neck cancer. Twenty adults who are already scheduled for a standard PET-CT scan will also receive a PCD-CT scan. Researchers will compare the images to see if the new scanner provides clearer pictures and better diagnostic confidence.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Photon counting detector CT (PCD-CT) imaging
- What this could lead to
- If successful, this could show that PCD-CT provides clearer PET images, potentially leading to better diagnosis and treatment planning for head and neck cancer.
- What could go wrong
- This is a very small pilot study (20 people) that is currently suspended. It only compares image quality and does not test any treatment or direct patient benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Scheduled for or completed standard-of-care PET-CT of head and neck within ≤30 days Exclusion Criteria: * Non-diagnostic PET-CT * Intervening therapy between scans * Iodinated contrast allergy * Renal insufficiency (GFR \< 45) * Pregnancy * Gross motion artifacts
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck cancer (H&N) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29407, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could daily swallowing exercises ease a harsh side effect of cancer treatment?
- Immune cells may hold the key to faster recovery after facial surgery
- Brain games may rev up thinking and driving after cancer treatment
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Heat and pulses: new combo therapy aims to soften cancer Treatment's harsh toll
- Bacteria in the mouth and gut may predict who responds to cancer immunotherapy